Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PPP5C | P53041 | 2/20 | 0.33 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125636 | 1.00 | CCR2 (0.38) | CCR2KCNH2ATMCYP1A2TDP1 | |
| SCHEMBL25728480 | 1.00 | CCR2 (0.38) | CCR2KCNH2ATMCYP1A2TDP1 | |
| SCHEMBL27627762 | 0.84 | CCR2 (0.34) | CCR2KCNH2 | |
| SCHEMBL27271348 | 0.84 | CCR2 (0.38) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL5307104 | 0.83 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL12108450 | 0.82 | CYP1A2 (0.39) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL13197230 | 0.82 | CYP1A2 (0.39) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL13448669 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL14754513 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL16003094 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-16 | — | — | US | disclosed |
| EP-4223759-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-108463728-B | Isobaric and ectopic mass marker | 电泳有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3387445-B1 | ISOBARIC MASS LABELS | ELECTROPHORETICS LTD (GB) | 2023-02-08 | — | — | EP | disclosed |
| EP-3387445-B1 | ISOBARIC MASS LABELS | ELECTROPHORETICS LTD (GB) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022266167-A1 | AMIDE AND UREA-CONTAINING TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11453621-B2 | Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties | ELECTROPHORETICS LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| CN-115073450-A | KRAS G12C Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073451-A | KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2022095904-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京伯汇生物技术有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | CCR2 1326/4885KCNH2 2476/4885ATM 4868/4885 |
| US-11453621-B2 | Isobaric mass labels having n',n'-dimeihyl piperazine-2-carboxylic acid reporter moieties | UCHL1, UCHL5, SRMS | CCR2 402/4885KCNH2 3395/4885ATM 4806/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2418/4885ATM 4605/4885 |
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | CCR2 2488/4885KCNH2 3354/4885ATM 1913/4885 |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | CCR2 2452/4885KCNH2 4815/4885ATM 4396/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | CCR2 615/4885KCNH2 856/4885ATM 3450/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | CCR2 865/4885KCNH2 363/4885ATM 4501/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | CCR2 93/4885KCNH2 465/4885ATM 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.